Marshall Wace LLP Cuts Stake in Sana Biotechnology, Inc. (NASDAQ:SANA)

Marshall Wace LLP lowered its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 94.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,322 shares of the company's stock after selling 372,359 shares during the quarter. Marshall Wace LLP's holdings in Sana Biotechnology were worth $35,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barclays PLC grew its stake in shares of Sana Biotechnology by 126.6% during the 3rd quarter. Barclays PLC now owns 318,910 shares of the company's stock valued at $1,325,000 after purchasing an additional 178,179 shares during the period. SG Americas Securities LLC bought a new stake in shares of Sana Biotechnology during the 4th quarter valued at $239,000. Charles Schwab Investment Management Inc. grew its position in shares of Sana Biotechnology by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock valued at $1,722,000 after acquiring an additional 8,666 shares during the period. Geode Capital Management LLC grew its position in shares of Sana Biotechnology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock valued at $5,206,000 after acquiring an additional 26,601 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Sana Biotechnology by 1,838.3% during the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company's stock valued at $521,000 after acquiring an additional 303,318 shares during the period. 88.23% of the stock is owned by institutional investors.

Sana Biotechnology Stock Up 12.9%

NASDAQ:SANA traded up $0.24 during mid-day trading on Monday, hitting $2.06. 863,190 shares of the stock traded hands, compared to its average volume of 3,301,786. The stock has a market capitalization of $463.36 million, a price-to-earnings ratio of -1.49 and a beta of 1.75. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $9.49. The firm's 50 day moving average is $1.93 and its two-hundred day moving average is $2.47.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. As a group, research analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on SANA shares. Jefferies Financial Group started coverage on Sana Biotechnology in a research note on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a research note on Thursday, April 24th. Finally, Citizens Jmp upgraded Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a research note on Tuesday, March 18th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $10.80.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.